Recommended Global Neuroscience Webinars & Conferences

Europe & UK

Neuropharmacology_2025, UK Neurology Conference 2026, France

Asia Pacific & Middle East

Neuroscience-2026, UAE

Canada

Neuropharmacology_2025

About Conference

We warmly welcome your participation at the 30th Global Experts Meeting on Neuroscience and Neuropharmacology, scheduled to take place on August 25–26, 2025, in London, UK. Centred on the theme "Exploring the Brain: Integrative Approaches to Neuroscience and Neuropharmacology," this distinguished event will spotlight cutting-edge advancements in brain research, therapeutic development, and neuropharmacological innovations.

The conference will bring together renowned experts from across the globe, providing a platform for dynamic discussions, international symposiums, workshops, and B2B networking opportunities. Key areas of focus will include Molecular and Cellular Neuroscience, Neurodegenerative Disorders, Behavioural Neuroscience, Psychopharmacology, Clinical Neuroscience, Drug Development, Neural Engineering, and more.

A major emphasis will be placed on understanding the mechanisms of neurological diseases and mental health disorders, and the development of novel pharmacological interventions. As neuropsychiatric conditions become increasingly prevalent worldwide, this event seeks to foster dialogue between academic researchers, clinicians, and pharmaceutical industry leaders to translate bench side discoveries into effective patient care.

Highlights Include:

In-depth sessions on neurotransmission, neuroinflammation, synaptic plasticity, and neurotoxicity
Insights into the treatment of Alzheimer’s, Parkinson’s, epilepsy, and mood disorders
Updates on neuropharmacological agents, Nano medicine, and targeted drug delivery systems
Panel discussions on personalized medicine and precision neuroscience

Student Poster Sessions and E-Posters:

We invite students and young investigators to present their innovative research through poster presentations. Abstracts will be published in Conference Series LLC Journals with DOI numbers. Those unable to attend in person can participate virtually via E-Posters.

Networking & B2B Opportunities:

The event offers valuable interaction with scientists, healthcare providers, investors, and biotech leaders. Whether through one-on-one meetings or digital networking platforms, participants will find ample opportunities for collaboration, partnerships, and career advancement.

Awards and Recognition:

To honour contributions in the field, the conference will present prestigious awards to Young Researchers, Postdoctoral Fellows, Graduate Students, and Junior Faculty, encouraging early-career scientists and professionals to engage and share their work with a global audience.

Why Attend?

This conference is a global gathering of Neuroscientists, Pharmacologists, Clinicians, Psychiatrists, Neurologists, Academicians, Biotech Professionals, and Students who are shaping the future of brain science and drug therapy. It is a unique opportunity to exchange insights, explore integrative approaches, and discuss the intersection of neuroscience and pharmacology for better diagnostics and treatments.

Target Audience:

Neuroscientists & Neurologists
Neuropharmacologists
Psychiatrists & Psychologists
Clinical Researchers
Drug Developers & Biotechnologists
Medical Practitioners
Academic Professionals & Students
Industrial Experts & Pharmaceutical Leaders

We look forward to welcoming you to London, UK, in August 2025 for this impactful and thought-provoking event in the world of Neuroscience and Neuropharmacology!

Session & Tracks

Track 1: Molecular and Cellular Neuroscience

Molecular and Cellular Neuroscience explores the biological building blocks of the nervous system, from neurons and glial cells to neurotransmitters and receptors. This track investigates the molecular mechanisms that control neuronal development, synaptic transmission, plasticity, and cell signalling. Researchers in this area study the intricate interactions of ion channels, enzymes, and gene expression that shape brain function and response to stimuli. Understanding these mechanisms helps explain how healthy brains develop and function—and how abnormalities contribute to conditions like epilepsy, neurodegeneration, and psychiatric disorders. This track is essential for bridging the gap between molecular insights and therapeutic strategies.

Track 2: Neuropharmacology and Drug Development

This track focuses on the development and action of drugs that influence nervous system function. Neuropharmacology studies how pharmaceutical agents affect neurotransmitter systems such as dopamine, serotonin, and GABA, which are critical for mood regulation, cognition, and pain processing. It covers both basic research and applied studies in drug discovery, efficacy testing, and side effect profiling. With neuropsychiatric disorders on the rise, this area is central to advancing safe and effective treatments. Attendees will explore preclinical models, receptor targeting strategies, and the latest innovations in CNS drug development including nanotechnology and precision medicine.

Track 3: Neurodegenerative Disorders

Neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and ALS affect millions globally, often with devastating personal and societal consequences. This track examines the cellular and molecular mechanisms underlying these conditions, including protein aggregation, mitochondrial dysfunction, oxidative stress, and synaptic failure. Discussions will also focus on genetic and environmental risk factors, early diagnostic biomarkers, and emerging therapeutic interventions. Presentations will explore the latest clinical trials, disease-modifying drugs, and non-pharmacological strategies aimed at improving patient outcomes and quality of life. This track is vital for developing approaches to slow, halt, or reverse neurodegeneration.

Track 4: Behavioural and Cognitive Neuroscience

This track investigates the neural basis of behaviour and cognition, exploring how brain processes underlie mental functions such as perception, memory, learning, attention, decision-making, and emotion. Researchers in this field use neuroimaging, electrophysiology, and behavioural studies to understand the brain circuits involved in everyday and pathological behaviours. Topics include the role of the prefrontal cortex, limbic system, and neurotransmitter systems in regulating mood and behaviour. The track also delves into how cognitive processes are altered in mental health disorders such as anxiety, depression, schizophrenia, and autism spectrum disorders. Insights from this field inform the development of targeted therapies and cognitive interventions.

Track 5: Clinical Neuroscience and Neurodiagnostics

Clinical neuroscience bridges laboratory discoveries with patient care by translating scientific research into diagnostic and therapeutic strategies. This track explores modern diagnostic tools including MRI, PET, EEG, MEG, and neurogenetic testing, which aid in the accurate detection and management of neurological diseases. Topics also include biomarkers for early disease detection, functional brain mapping, and the use of neuroinformatics in clinical decision-making. Participants will engage with current trends in personalized medicine and evidence-based practices for treating disorders such as epilepsy, multiple sclerosis, brain tumours, and stroke. The track emphasizes the role of technology in enhancing patient outcomes.

Track 6: Neuroinflammation and Immune Response

Neuroinflammation is a critical component in the pathogenesis of numerous central nervous system disorders, including multiple sclerosis, Alzheimer’s disease, and traumatic brain injury. This track explores the interactions between the nervous and immune systems, focusing on microglial activation, cytokine signalling, blood-brain barrier dysfunction, and immune cell infiltration into the brain. Researchers will examine both the protective and damaging roles of inflammation in acute and chronic conditions. Sessions will also cover current therapeutic strategies aimed at modulating the immune response to reduce neural damage and improve recovery. By understanding neuroimmune dynamics, this track paves the way for targeted immunotherapies in neurology.

Track 7: Psychiatric Disorders and Psychopharmacology

This track delves into the complex neurobiology of psychiatric illnesses, including depression, bipolar disorder, anxiety, schizophrenia, and PTSD. Attendees will explore how imbalances in neurotransmitter systems such as serotonin, dopamine, and norepinephrine influence mood and behaviour. Psychopharmacology sessions will focus on the development and clinical use of antidepressants, antipsychotics, mood stabilizers, and anxiolytics. The track will highlight recent advancements in pharmacogenomics, personalized medicine, and the role of neuroinflammation in psychiatric pathology. Cutting-edge research on psychedelic-assisted therapy and novel targets like ketamine will also be presented. This track is vital for anyone interested in the evolving landscape of mental health treatment.

Track 8: Neurogenetics and Epigenetics

Neurogenetics investigates how genetic variation influences brain structure, function, and susceptibility to neurological diseases. This track focuses on the role of inherited mutations, gene expression patterns, and epigenetic modifications in disorders such as epilepsy, autism, and neurodevelopmental syndromes. It will also explore genome-wide association studies (GWAS), CRISPR gene-editing technology, and next-generation sequencing as tools for understanding the genetic basis of brain disorders. Epigenetics, including DNA methylation and histone modification, is increasingly recognized as a dynamic mediator of gene-environment interactions. Presentations in this track will show how these factors contribute to cognitive development, brain plasticity, and disease progression.

Track 9: Pain Mechanisms and Management

Chronic pain affects nearly one in five adults worldwide and presents a major healthcare challenge. This track explores the neurobiological mechanisms underlying both acute and chronic pain, including nociceptive pathways, central sensitization, and the role of glial cells. Topics include neuropathic pain, migraine, fibromyalgia, and cancer-related pain. Sessions will cover pharmacological treatments such as opioids, NSAIDs, and emerging agents like cannabinoids and sodium channel blockers. Non-pharmacological approaches, including neuromodulator, cognitive behavioural therapy, and physiotherapy, will also be discussed. By integrating basic science with clinical approaches, this track seeks to improve pain assessment and develop individualized treatment strategies.

Track 10: Neuroplasticity and Brain Repair

Neuroplasticity refers to the brain’s remarkable ability to adapt and reorganize itself in response to learning, injury, or disease. This track examines how neuroplasticity changes occur at cellular, synaptic, and network levels, and how these mechanisms can be harnessed to support recovery and rehabilitation. Topics include adult neurogenesis, synaptic strengthening and pruning, and functional reorganization following stroke or trauma. Researchers will discuss strategies to stimulate plasticity, including pharmacological agents, brain stimulation, cognitive training, and enriched environments. This field holds great promise for advancing recovery in patients with neurodegenerative diseases, brain injuries, and developmental disorders.

Track 11: Addiction and Neurobehavioral Science

Addiction is a complex brain disorder characterized by compulsive substance use despite harmful consequences. This track explores the neurobehavioral mechanisms that underlie addiction, focusing on the brain’s reward system, particularly the role of dopamine in the mesolimbic pathway. Sessions will examine how substances such as opioids, alcohol, nicotine, and stimulants alter neural circuits responsible for motivation, decision-making, and impulse control. Behavioural neuroscience approaches, including animal models and neuroimaging studies, provide insight into craving, relapse, and tolerance. The track also includes new therapeutic strategies like cognitive-behavioural therapy, pharmacological treatments, harm reduction models, and innovative interventions using digital therapeutics and neuromodulation.

Track 12: Neurovascular Biology and Stroke

Neurovascular biology examines the intricate relationship between blood vessels and neural tissue, a connection vital for brain health and function. This track will explore stroke pathology, cerebral blood flow regulation, endothelial dysfunction, and the role of inflammation in cerebrovascular events. Stroke remains a leading cause of disability worldwide, and sessions will focus on early detection, emergency care, and rehabilitation strategies. Key discussions include thrombolytic therapy, endovascular procedures, and post-stroke neuroplasticity. Additionally, researchers will examine blood-brain barrier integrity, angiogenesis, and how vascular health impacts neurodegenerative diseases. This track offers critical insights for neurologists, neurosurgeons, and rehabilitation specialists.

Track 13: Computational Neuroscience and Brain Mapping

This track focuses on the application of computational models, simulations, and advanced imaging techniques to understand brain function and structure. Computational neuroscience helps decode how networks of neurons process information, from sensory input to motor control. Topics include neural coding, synaptic dynamics, and large-scale brain simulations. Brain mapping techniques such as fMRI, EEG, and connect omics are highlighted, offering high-resolution views of neural connectivity and function. Participants will explore how artificial intelligence and machine learning are revolutionizing neuroscience research and clinical practice. The track also examines brain-computer interfaces and neuroinformatics platforms that integrate massive datasets for personalized medicine.

Track 14: Neuro-oncology

Neuro-oncology focuses on the diagnosis, treatment, and research of tumours affecting the brain and spinal cord. This track highlights advancements in understanding the molecular genetics and cellular biology of brain tumours, including glioblastoma, medulloblastoma, and metastatic brain cancers. Topics include tumour microenvironment, angiogenesis, and immune evasion mechanisms. Clinicians and researchers will discuss innovative treatment approaches such as immunotherapy, targeted molecular therapies, stereotactic radiosurgery, and precision surgery. Emphasis will also be placed on early detection biomarkers and clinical trial outcomes. This track bridges research and clinical care to improve survival rates and quality of life for patients with CNS malignancies.

Track 15: Pediatric Neurology and Neurodevelopment

Pediatric neurology addresses neurological conditions that appear during infancy and childhood, many of which impact lifelong development. This track will explore disorders such as epilepsy, cerebral palsy, autism spectrum disorder, developmental delay, and rare genetic syndromes. Emphasis will be placed on early diagnostic strategies, neuroimaging, and genetic testing to identify conditions at the earliest stages. Presentations will also focus on neurodevelopmental milestones, behavioural comorbidities, and the impact of neuroplasticity on rehabilitation. Current and emerging treatments, including antiepileptic drugs, neurorehabilitation techniques, and non-invasive brain stimulation, will be discussed. The track supports an integrative approach to improving outcomes in paediatric brain health.

Track 16: Sleep Disorders and Chronobiology

Sleep is essential for cognitive function, emotional regulation, and physical health. This track explores the neurobiological mechanisms governing sleep-wake cycles and circadian rhythms. Topics include common sleep disorders such as insomnia, sleep apnea, narcolepsy, restless leg syndrome, and REM behaviour disorder. Researchers will discuss the neural circuits involved in sleep regulation, the role of neurotransmitters like melatonin and orexin, and the impact of sleep on memory and mental health. Advances in sleep monitoring, wearable technology, and the pharmacology of sleep aids will be covered. This track is vital for understanding how disrupted sleep contributes to neurological and psychiatric disorders and for developing evidence-based treatments.

Track 17: Neuromodulation and Neurotechnology

Neuromodulation involves targeted delivery of electrical, magnetic, or chemical stimuli to modulate neural activity. This rapidly evolving field holds promise for treating conditions like chronic pain, depression, epilepsy, and Parkinson’s disease. This track will cover deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), spinal cord stimulation, and emerging wearable neurotechnologies. Topics also include implantable brain-machine interfaces and closed-loop systems that adapt stimulation in real time. Researchers and clinicians will explore safety, efficacy, and future applications of neurotechnology in both therapeutic and enhancement contexts. This track is ideal for those interested in merging engineering, neuroscience, and clinical innovation.

Track 18: Neuroethics and Mental Health Policy

As neuroscience advances, so do the ethical, legal, and societal implications of brain research and neurotechnology. This track explores critical issues such as informed consent in cognitive trials, data privacy in brain imaging, and the use of neuroenhancement tools in healthy individuals. Topics include the ethics of AI in mental health, equitable access to neurological care, and the impact of stigma on mental health outcomes. Policy discussions will focus on global mental health frameworks, disparities in neurological treatment, and advocacy for brain health as a human right. This track invites interdisciplinary dialogue between scientists, ethicists, policymakers, and clinicians.

Track 19: Aging, Dementia, and Cognitive Decline

As life expectancy increases globally, age-related cognitive decline and dementia present significant public health challenges. This track focuses on the biological and environmental factors that influence brain aging, with an emphasis on Alzheimer’s disease, vascular dementia, and mild cognitive impairment (MCI). Sessions will cover early detection methods using neuroimaging, blood-based biomarkers, and cognitive testing. Participants will explore therapeutic interventions, from pharmacologic agents and lifestyle modifications to cognitive training and digital therapeutics. The track also highlights caregiver support and health policy issues. Understanding the aging brain is key to developing strategies that preserve mental function and enhance quality of life.

Track 20: Neurotoxicity and Environmental Neuroscience

Environmental exposures can profoundly affect brain health, particularly during critical periods of development. This track investigates how heavy metals, pesticides, air pollutants, endocrine disruptors, and recreational drugs contribute to neurotoxicity. Sessions will examine mechanisms such as oxidative stress, mitochondrial dysfunction, and inflammation that underlie environmental damage to the nervous system. Special emphasis will be placed on vulnerable populations, including children and pregnant women. Researchers will also discuss policy measures, public health strategies, and novel protective interventions aimed at reducing environmental risks. This track bridges neuroscience and environmental health to promote safer living conditions and informed regulation.

Market Analysis

The global landscape of neuroscience and neuropharmacology is witnessing significant transformation, driven by the growing burden of neurological disorders, rapid advancements in neurotechnologies, and an increasing emphasis on precision medicine. Neurological diseases such as Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis, and depression contribute to a substantial portion of the global disease burden, necessitating urgent attention from the healthcare and research communities.

Market Size and Growth

The global neuroscience market was valued at USD 34.2 billion in 2024, and it is projected to reach approximately USD 56.1 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.5%. The neuropharmacology segment alone is expected to surpass USD 22 billion by the end of this decade, propelled by increasing R&D efforts, innovations in drug delivery systems, and the rising adoption of biologics and targeted therapies.

Key Market Drivers

Rising Prevalence of Neurological Disorders: A growing aging population and improved diagnostics have contributed to higher reported cases of cognitive, neurodegenerative, and neurodevelopmental disorders.
Technological Advancements: Innovations in neuroimaging, brain mapping, artificial intelligence, and neuroinformatics are transforming the way neurological diseases are understood and treated.
Pharmaceutical and Biotech Innovation: Increased investments in CNS drug discovery, personalized medicine, and gene-based therapies are expanding the therapeutic pipeline.
Digital Health Integration: The use of digital therapeutics, wearable devices, and brain-computer interfaces is reshaping patient care and remote neurological monitoring.

Regional Trends

North America remains the largest market, driven by advanced research facilities, regulatory support, and robust healthcare infrastructure.
Europe shows strong growth with increased clinical trials and strategic public-private collaborations.
Asia-Pacific is the fastest-growing region, supported by rising healthcare expenditure, expanding awareness, and significant patient population.

Opportunities and Challenges

The sector presents substantial opportunities in developing novel therapeutics, neurotechnologies, and integrative treatment approaches. However, challenges persist in terms of high development costs, regulatory complexities, and the intricate nature of brain disorders that often lack definitive biomarkers or treatments.

Conclusion

The neuroscience and neuropharmacology market is poised for continued expansion, underpinned by scientific breakthroughs and interdisciplinary collaboration. The 30th Global Experts Meeting on Neuroscience and Neuropharmacology serves as a vital forum for researchers, clinicians, industry professionals, and policymakers to share insights, foster innovation, and address global neurological health challenges. By facilitating dialogue and partnerships, the conference contributes to shaping the future of neuroscience research and patient care.

To Collaborate Scientific Professionals around the World

Conference Date August 25-26, 2025

For Sponsors & Exhibitors

sponsor@conferenceseries.com

Speaker Opportunity

Poster Opportunity E-Poster Opportunity

Useful Links

Past Conference Report

Neuropharmacology_2023 Conference

Supported By

All accepted abstracts will be published in respective Conference Series International Journals.

Abstracts will be provided with Digital Object Identifier by

Neuroscience and Neuropharmacology

August 25-26, 2025 London, UK

Exploring the Brain: Integrative Approaches to Neuroscience and Neuropharmacology

Conference Series Conferences gaining more Readers and Visitors